CD274 and cancer: An interesting finding from this study was that one of the leads tested, CLP001, did not share a significant interaction surface area with PD-1, confirmed by blocking studies that showed little to no blocking efficiency of the human PD-1/PD-L1 interaction using recombinant PD-L1 and PD-L1 positive cancer cells (202).